Acyl-CoA Synthetase Activity Links Wild-Type but Not Mutant α-Synuclein to Brain Arachidonate Metabolism[†]

Mikhail Y. Golovko,[‡] Thad A. Rosenberger,[‡] Nils J. Færgeman,[§] Søren Feddersen,[∥] Nelson B. Cole,[⊥]
Ingrid Pribill,[@] Johannes Berger,[@] Robert L. Nussbaum,[⊥] and Eric J. Murphy*,[‡,§]

*Department of Pharmacology, Physiology, and Therapeutics and Department of Chemistry, University of North Dakota,
Grand Forks, North Dakota 58202-9037, Department of Biochemistry and Molecular Biology, University of Southern Denmark,
DK-5230 Odense M, Denmark, Genetic Disease Research Branch, National Human Genome Research Institute, National
Institutes of Health, Bethesda, Maryland 20892-4448, and Division of Neuroimmunology, Center for Brain Research Institute,
Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria*

Received January 5, 2006; Revised Manuscript Received April 15, 2006

ABSTRACT: Because α-synuclein (Snca) has a role in brain lipid metabolism, we determined the impact that the loss of α-synuclein had on brain arachidonic acid (20:4n-6) metabolism in vivo using $Snca^{-/-}$ mice. We measured $[1\text{-}^{14}C]20\text{:}4n\text{-}6$ incorporation and turnover kinetics in brain phospholipids using an established steady-state kinetic model. Liver was used as a negative control, and no changes were observed between groups. In $Snca^{-/-}$ brains, there was a marked reduction in 20:4n-6-CoA mass and in microsomal acyl-CoA synthetase (Acsl) activity toward 20:4n-6. Microsomal Acsl activity was completely restored after the addition of exogenous wild-type mouse or human α-synuclein, but not by A30P, E46K, and A53T forms of α-synuclein. Acsl and acyl-CoA hydrolase expression was not different between groups. The incorporation and turnover of 20:4n-6 into brain phospholipid pools were markedly reduced. The dilution coefficient λ, which indicates 20:4n-6 recycling between the acyl-CoA pool and brain phospholipids, was increased 3.3-fold, indicating more 20:4n-6 was entering the 20:4n-6-CoA pool from the plasma relative to that being recycled from the phospholipids. This is consistent with the reduction in Acsl activity observed in the $Snca^{-/-}$ mice. Using titration microcalorimetry, we determined that α-synuclein bound free 20:4n-6 ($K_d = 3.7\ \mu M$) but did not bind 20:4n-6-CoA. These data suggest α-synuclein is involved in substrate presentation to Acsl rather than product removal. In summary, our data demonstrate that α-synuclein has a major role in brain 20:4n-6 metabolism through its modulation of endoplasmic reticulum-localized acyl-CoA synthetase activity, although mutant forms of α-synuclein fail to restore this activity.

α-Synuclein is a 140-amino acid soluble protein that is strongly expressed in the central nervous system (*1, 2*) and is abundant in presynaptic terminals of neurons (*1, 3–5*). α-Synuclein is also found in other regions of neurons, in astrocytes, and in oligodendroglia (*6–11*). Overexpression of and mutations in α-synuclein are associated with early onset Parkinson's disease (*12–15*) and other neurodegenerative diseases (*16–20*). Despite this association with neurodegenerative diseases, the physiological function of this protein remains unclear.

Several lines of evidence suggest that α-synuclein can influence brain lipid metabolism. It is structurally similar to class A2 apolipoproteins (*21, 22*) and to fatty acid binding proteins (*23*), suggesting that α-synuclein may alter intracellular lipid trafficking and the regulation of lipid metabolism and may act to stabilize lipid membranes. α-Synuclein binds to small phospholipid vesicles (*22, 24, 25*) and to brain vesicles (*26*). Consistent with this binding, the lack of α-synuclein decreases the size of the resting/reserve pool of synaptic vesicles (*27, 28*). Although the direct binding of fatty acids is controversial (*23, 29*), recent studies indicate a strong potential for an important role of α-synuclein in fatty acid uptake and metabolism (*11, 29, 30*). In astrocytes lacking α-synuclein palmitic (16:0) and arachidonic (20:4n-6)[1] acid, uptake and metabolism are reduced through an unknown mechanism (*11*). Lack of α-synuclein in brain depresses 16:0 uptake and significantly alters its metabolism (*29*), although the impact on brain 20:4n-6 uptake and metabolism is unknown.

In addition, α-synuclein modulates phospholipase C and D activities in vitro (*22, 31–33*), suggesting a role in lipid-mediated signal transduction. Studies in vivo also demonstrate that α-synuclein affects enzymes involved in lipid metabolism, because α-synuclein overexpression leads to phospholipase D inhibition in yeast (*34*) and downregulates expression of phospholipase A₂ and of long chain fatty acid

* To whom correspondence should be addressed: Department of Pharmacology, Physiology, and Therapeutics, School of Medicine and Health Sciences, University of North Dakota, 501 N. Columbia Rd., Grand Forks, ND 58202-9037. E-mail: emurphy@medicine.nodak.edu. Phone: (701) 777-3450. Fax: (701) 777-4490.
‡ Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota.
§ Department of Chemistry, University of North Dakota.
∥ University of Southern Denmark.
⊥ National Institutes of Health.
@ Medical University of Vienna.

CoA synthetase in *Drosophila* (*35*). These additional findings suggest that α-synuclein impacts lipid-mediated signal transduction, including 20:4n-6 release. Release of 20:4n-6 during signal transduction is crucial for proper CNS function (*36*−*41*) and pathophysiological responses (*42*−*45*).

To address the potential role for α-synuclein in brain 20:4n-6 uptake and metabolism, we used steady-state kinetic modeling of [1-^{14}C]20:4n-6 metabolism in vivo coupled with studies using enzyme assays and mRNA expression of key fatty acid metabolic enzymes. These data show, for the first time, a mechanistic explanation for the impact of α-synuclein deficiency on brain lipid metabolism. Herein, we demonstrate that, in the absence of α-synuclein, brain microsomal acyl-CoA synthetase activity was decreased, which in turn reduced the rates of 20:4n-6 uptake and turnover in brain phospholipid pools. More importantly, addition of wild-type (wt) human or mouse α-synuclein completely restored acyl-CoA synthetase activity in these microsomes, while the A30P, E46K, and A53T mutant forms of α-synuclein failed to restore activity.

MATERIALS AND METHODS

Mice. This study was conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (NIH Publication 80-23) and under an animal protocol approved by the IACUC at the University of North Dakota (Protocol 0110-1). α-Synuclein gene-ablated mice (*Snca*$^{-/-}$) were produced from the 129/SvEv strain by gene-targeted deletion (*28*). Male mice (25−30 g) were maintained on standard laboratory chow diet and water ad libitum. The ages of the mice used in this study were between 9 and 11 months in both groups.

Mouse Surgery and Tracer Infusion. The mouse surgery and tracer infusion was performed as previously described (*29, 46, 47*). Briefly, [1-^{14}C]20:4n-6 (Moravek Biochemical, Brea, CA) was solubilized in 5 mM HEPES (pH 7.4) buffer containing "essentially fatty acid free" bovine serum albumin (50 mg/mL, Sigma Chemical Co., St. Louis, MO). Awake (3−4 h post-operative) fasted, male mice (*Snca*$^{+/+}$ or *Snca*$^{-/-}$) were infused with 170 μCi/kg of [1-^{14}C]20:4n-6 via the femoral vein over 10 min at a constant rate of 30 μL/min. Prior to and during the infusion, arterial blood samples (~20 μL) were taken to determine plasma radioactivity and confirm steady-state plasma radioactivity. Following infusion, each mouse was killed using pentobarbital (100 mg/kg, intravenous) and immediately subjected to focused microwave irradiation to heat denature enzymes in situ. Brain and liver were rapidly removed, frozen in liquid nitrogen, and pulverized under liquid nitrogen temperatures to a fine, homogeneous powder.

---

[1] Abbreviations: *Snca*, α-synuclein; *Acsl*, acyl-CoA synthetase; *Bach*, acyl-CoA hydrolase mRNA; *36B4*, acidic ribosomal phosphoprotein P0 (italics for the gene and nonitalics for the protein); EtnGpl, ethanolamine glycerophospholipids; PtdIns, phosphatidylinositol; PtdSer, phosphatidylserine; ChoGpl, choline glycerophospholipids; Cer-PCho, sphingomyelin; 20:4n-6, arachidonic acid; k_i*, coefficient for incorporation of 20:4n-6 from plasma into an individual phospholipid; $J_{FA,i}$, net rate of incorporation from 20:4n-6-CoA into an individual phospholipid; $T_{1/2,i}$, half-life of 20:4n-6 in an individual phospholipid; k*(20:4-CoA), coefficient for incorporation of 20:4 from plasma into the 20:4-CoA pool; [20:4-CoA], mass of 20:4-CoA in tissue; λ, dilution coefficient; incorp. rate 20:4-CoA, net rate of incorporation of 20:4 from 20:4-CoA into individual phospholipids; FATP, fatty acid binding protein.

Lipid Extraction. Lipids from the tissue powder, plasma, and blood samples were extracted using a two-phase extraction procedure (*48*). The radioactivity in the aqueous and organic fractions was determined by liquid scintillation counting. The extracts were concentrated under a stream of N$_2$ at 40 °C and dissolved in an *n*-hexane/2-propanol/water mixture (56.7:37.8:5.5 by volume).

Thin-Layer Chromatography. Tissue phospholipids (PL) were separated by thin-layer chromatography (TLC) on heat-activated Whatman silica gel-60 plates (20 cm × 20 cm, 250 μm) and developed in a chloroform/methanol/acetic acid/water mixture (55:37.5:3:2 by volume) (*49*). Brain, liver, and plasma neutral lipids (NL) were separated by TLC on heat-activated Whatman silica gel-60 plates (20 cm × 20 cm, 250 μm) and developed in a petroleum ether/diethyl ether/acetic acid mixture (75:25:1.3 by volume) (*50*). Once separated, individual PL and NL were isolated and used to quantify individual PL and NL class fatty acid masses and radioactivities.

Gas−Liquid Chromatography. The 20:4n-6 mass in phosphatidylinositol (PtdIns), phosphatidylserine (PtdSer), choline glycerophospholipids (ChoGpl), and ethanolamine glycerophospholipids (EtnGpl) was determined following base-catalyzed transesterification to form the fatty acid methyl esters (*51*). Sphingomyelin (CerPCho) individual fatty acid masses, as well as the mass of free fatty acids in plasma, brain, and liver, were measured by gas−liquid chromatography (GLC) after acid-catalyzed esterification (*52*). The gas−liquid chromatograph (Trace GC, ThermoElectron, Austin, TX) was equipped with a capillary column (SP 2330; 30 m × 0.32 mm inside diameter, Supelco, Bellefonte, PA) and a flame ionization detector. Fatty acids were quantified using a standard curve from commercially purchased standards (NuChek Prep, Elysian, MN), and 17:0 was the internal standard (*29*).

Acyl-CoA Extraction, Separation, and Quantification. Acyl-CoA from brain and acyl-CoA from liver were extracted and purified using a solid-phase extraction procedure and separated by HPLC on a C-18(2) column (Luna, Phenomenex, Torrance, CA) (*53*). The system was controlled with a Beckman (Fullerton, CA) 127 solvent module. The eluent was monitored at 260 nm using a Beckman 166 UV−vis detector (*53*). The mass of 20:4n-6-CoA was determined using a standard curve from commercially purchased standards (Sigma Chemical Co.), and 17:0-CoA was the internal standard. The radioactivity of 20:4n-6-CoA was determined by liquid scintillation counting.

Liquid Scintillation Counting. Samples were placed into 20 mL liquid scintillation vials, and 0.5 mL of H$_2$O was added, followed by 10 mL of Scintiverse BD (Fisher). After mixing was carried out, the samples were quantified by liquid scintillation counting using a Beckman LS5000 CE liquid scintillation counter (Beckman Instruments) for at least 1 h after the addition of the liquid scintillation mixture.

Kinetic Analysis. Our study was performed under steady-state conditions using a quantitative kinetic model as previously described (*29, 36, 54−56*). The main aspect of this model is that it accounts for fatty acid recycling between phospholipid pools and the acyl-CoA pool. The dilution coefficient, λ, represents this recycling and is defined as the steady-state specific activity of brain 20:4n-6-CoA relative to the specific activity of plasma 20:4n-6.

Titration Microcalorimetry. Titration microcalorimetry was carried out as previously described (*29*, *57*). Briefly, recombinant α-synuclein (50 μM) was titrated with 20:4n-6 at 27 °C in 20 mM potassium phosphate buffer containing 50 mM KCl (pH 7.2). The sample was titrated with 25−30 aliquots of the fatty acid-containing solution (1 mM) added at 3 min intervals. Raw data were integrated using the supplied ORIGIN software (MicroCal, Inc.), and isotherms were analyzed as previously described (*58*, *59*).

Northern Blot Analysis. Northern blot analysis was carried out as previously described (*60*). Briefly, 20 μg of isolated mRNA from *Snca$^{-/-}$* and *Snca$^{+/+}$* mouse brains was resolved on a 1.2% agarose−formaldehyde gel and transferred to a Biodyne B membrane. Probes were chosen for each Acsl that were for specific regions of the mRNA that differed significantly from each other. Probes were radioactively labeled by random priming using [α-^{32}P]dCTP and High Prime solution (Roche). A murine cDNA (positions 9−969; GenBank accession number BC011106) of the ubiquitously expressed acidic ribosomal phosphoprotein P0 (36B4) was used as a loading control. To detect murine *Acsl3*, *Acsl4*, *Acsl6*, and *Bach* mRNA, the following probes were used: mouse *Acsl3* fragment of 342 bp (nucleotides 1060−1402 of accession number NM_028817), mouse *Acsl4* cDNA fragment of 329 bp (nucleotides 878−1206 of accession number NM_019477), mouse *Acsl6* fragment of 398 bp (nucleotides 877−1274 of accession number NM_144823), and mouse *Bach* cDNA fragment of 386 bp (positions 559−944 of accession no. NM_133348). The blot was hybridized using ExpressHyb solution (BD Biosciences, Franklin Lakes, NJ) at 68 °C and washed to high stringency according to the manufacturer's instructions.

Changes in *Acsl6* expression were confirmed using quantitative real-time PCR. For each assay, 4 ng of cDNA (generated with a GeneAmp RNA PCR kit, Applied Biosystems) was analyzed using the iCycler iQ real-time PCR detection system (Bio-Rad). Mouse *Acsl6* expression was quantified using primers nt877 [5′-atagaggactgtggccgaga-3′ (forward)] and nt979 [5′-ctttggggttccctgttgta-3′ (reverse)] (accession number NM_144823) with Sybr-Green. As a control, hydroxyphosphoribosyl transferase (*Hprt*) mRNA levels were quantified using the primers nt503 [5′-ctggtaaaacaatgcaaac-3′ (forward)], nt622 [5′-caaagtctggcctgtatc-3′ (reverse)], nt569 [5′-FAM-caagcttgctggtgaaaagga-DABCYL-3′ (TaqMan probe)]. Standard curves were generated by serial dilution of plasmids containing *Acsl6* or *Hprt* cDNA (kindly provided by D. W. Melton, University of Edinburgh, Edinburgh, U.K.). The thermocycler was programmed as follows: 95 °C for 10 min followed by 50 cycles at 95 °C for 20 s and 58 °C for 50 s for *Hprt* and 95 °C for 10 min followed by 35 cycles at 95 °C for 10 s and 60 °C for 50 s for *Acsl6*. At the end of the *Acsl6* Sybr-Green detection, a melt curve was performed for each well to ensure the absence of unspecific PCR products.

Brain Homogenate and Brain Microsome-Associated Acyl-CoA Synthetase Activity. Brain microsomal fractions, from wt and *snca$^{-/-}$* mice, containing acyl-CoA synthetases were prepared by centrifugation, and long chain fatty acyl-CoA synthetase activity was measured (*61*, *62*). The protein content in the microsomal fraction and whole brain homogenate was measured using a dye binding assay (*63*). Acsl activity was measured in three different groups: (1) microsomes from wt mice, (2) microsomes from *snca$^{-/-}$* mice, and (3) microsomes from *snca$^{-/-}$* mice incubated with 1.0 wt % mouse α-synuclein for 30 min. In all groups, Acsl activity was measured in the whole brain homogenate or in the microsomal homogenate by adding 20 μg of protein to the assay cocktail, containing 670 μM Triton X-100, having a final [1-^{14}C]20:4n-6 concentration between 3.6 and 190 μM. The reactions were terminated after incubation at 37 °C for 4 min. After extraction of nonesterified 20:4n-6, the radioactivity of 20:4n-6-CoA was determined by liquid scintillation counting. The initial rates of reaction were calculated on the basis of the specific radioactivity of the reaction substrate. The V_{max} and K_m of Acsl activity with 20:4n-6 as a substrate were calculated using standard Michaelis−Menten kinetic analysis.

Rescue of Acyl-CoA Synthetase Activity. Purified, recombinant human and mouse wt α-synuclein or its mutant forms (A30P, E46K, and A53T) were purified (*64*) and used to determine if these different forms of α-synuclein could rescue microsomal Acsl activity. To determine which concentration of wt or mutant α-synuclein was the ideal concentration for the restoration of Acsl activity, we incubated microsomes with 0.01−10% α-synuclein relative to total microsomal protein. This corresponds to a final concentration for α-synuclein of 0.6−634 μM in the assay. The α-synuclein, in Tris buffer (pH 7.4), was added 30 min prior to incubation of the *Snca$^{-/-}$* brain microsomal fractions (20 μg of protein) with [1-^{14}C]20:4n-6 (190 μM). Acsl activity was determined as stated above. To assess the potential endogenous acyl-CoA synthetase activity of α-synuclein, recombinant α-synuclein (1.2 μg) was added to 50 μL of solubilization buffer, which was then added to the assay cocktail.

Western Blot Analysis of α-Synuclein. Brain microsomal protein (40 μg) from *Snca$^{+/+}$* mice ($n = 8$) was resolved on a 15% polyacrylamide gel and transferred to a PVDF membrane (*11*, *65*). The positive control was the recombinant α-synuclein, and the antibody used to detect α-synuclein was monoclonal anti-synuclein antibody 4D6 (1:1000, Signet, Dedham, MA). Blots were developed using the chemiluminescence supersignal (Amersham, Piscataway, NJ).

Statistics. Statistical significance was assessed using an unpaired, two-way, Student's *t* test, with a *p* of <0.05 considered to be statistically significant. For microsomal Acsl assays, statistical significance was assessed using a one-way ANOVA and a Tukey-Kramer post hoc test, with a *p* of <0.05 considered to be significant. The number of mice used per experiment is indicated in the figure and table legends.

RESULTS

α-*Synuclein Binds 20:4n-6 but Not 20:4n-6-CoA.* We have shown that α-synuclein does not bind palmitate or oleate using titration microcalorimetry (*29*), although others have shown oleate binding using the classical Lipidex assay (*23*). To assess if α-synuclein bound monomeric 20:4n-6, we again used titration microcalorimetry. We determined that α-synuclein bound 20:4n-6 with a K_d of 3.7 ± 1.7 μM ($n = 3$) (Figure 1a) but did not bind 20:4n-6-CoA (Figure 1b). The binding affinity for 20:4n-6 is 1−2 orders of magnitude lower than that of a classical FABP (*66*).

*The Absence of α-Synuclein Reduced Brain 20:4n-6-CoA Mass.* We noted that the mass of the brain 20:4n-6-CoA pool

FIGURE 1: (a) α-Synuclein binding of 20:4n-6 as determined using titration microcalorimetry ($n = 3$). (b) Lack of α-synuclein binding of 20:4n-6-CoA as determined using titration microcalorimetry ($n = 3$).

FIGURE 2: (a) Mass of 20:4n-6-CoA in brain and liver isolated from $snca^{-/-}$ and $snca^{+/+}$ mice. Values represent means ± the standard deviation ($n = 8-10$). The asterisk indicates a statistically significant difference from $snca^{+/+}$ mice ($p < 0.05$). (c) Dilution coefficient λ for $snca^{-/-}$ and $snca^{+/+}$ mice. Values represent means ± the standard deviation ($n = 8-10$). The asterisk indicates a statistically significant difference from $snca^{+/+}$ mice ($p < 0.05$).

was reduced 58% in the $Snca^{-/-}$ mice while the mass in liver 20:4n-6-CoA was unchanged (Figure 2a). Because liver tissue does not contain α-synuclein (*29*), we used it as a negative control in these experiments. A reduced rate of incorporation of 20:4n-6 from plasma into the brain 20:4n-6-CoA pool did not account for this reduction in brain 20:4n-6-CoA mass (k^*), as these values were equivalent between groups (data not shown). This indicates that the smaller 20:4n-6-CoA pool was not the result of a reduction in the level of plasma-derived 20:4n-6, but rather from a potential reduction in the level of 20:4n-6 recycling from brain phospholipid pools. This was confirmed by an increase in the dilution coefficient, λ, in the $Snca^{-/-}$ brains, indicating an increase in the amount of fatty acid entering the 20:4n-6-CoA pool via the plasma relative to the amount coming from the recycling of 20:4n-6 from endogenous phospholipid pools (Figure 2b). From these results, we would predict that the markedly smaller 20:4n-6-CoA pool would cause a reduction in the rate of incorporation of 20:4n-6-CoA into $Snca^{-/-}$ brain phospholipid pools.

The Absence of α-*Synuclein Decreased the Rate of Incorporation of Brain 20:4n-6-CoA into Phospholipids.* We next examined the impact of α-synuclein deficiency on changes in the kinetics of 20:4n-6 incorporation and turnover in brain phospholipid pools. In brain tissue, we found the incorporation coefficient k^* for 20:4n-6 entering PtdIns, PtdSer, ChoGpl, and CerPCho was decreased 25, 34, 22, and 50%, respectively, in $Snca^{-/-}$ compared to $Snca^{+/+}$ mice (Table 1). The rates of incorporation ($J_{FA,i}$) of 20:4n-6-CoA into EtnGpl, PtdIns, PtdSer, ChoGpl, and CerPCho were also decreased 48, 46, 41, 47, and 66%, respectively, in $Snca^{-/-}$ compared to $Snca^{+/+}$ mice. As a result, the half-life ($T_{1/2}$) for 20:4n-6 in brain EtnGpl, PtdIns, PtdSer, ChoGpl, and CerPCho was increased 2.8-, 3.3-, 2.4-, 2.9-, and 3.7-fold, respectively, in $Snca^{-/-}$ mice compared to $Snca^{+/+}$ mice. Importantly, there were no significant differences in liver individual phospholipid kinetics between groups (Table 2), indicating that these changes were brain specific.

While this reduction in the amount of 20:4n-6-CoA affected the kinetics of incorporation of 20:4n-6 into brain phospholipid pools, it did not cause a reduction in the absolute mass of 20:4n-6 in individual brain phospholipids (Table 1). These results are consistent with a reduction in the amount of 20:4n-6-CoA available as substrate for phospholipid fatty acid remodeling. We then turned our attention to examining whether this effect was mediated by a decreased rate of synthesis of 20:4n-6-CoA and 20:4n-6 uptake.

The Absence of α-*Synuclein Reduced the Rate of Brain 20:4n-6 Uptake.* Previously, we demonstrated that α-sy-

Table 1: Effects of α-Synuclein Ablation on the Unilateral Incorporation Coefficient (k_i*), the Rate of Incorporation into Individual Brain Phospholipid Pools, and Turnover in These Individual Phospholipid Pools[a]

	k_i* ($\times 10^{-5}$ s^{-1})		$J_{FA,i}$ (nmol/h)		$T_{1/2,i}$ (h)		$C_{br,i}$ (nmol/g wet weight)	
	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$
EtnGpl	2.7 ± 0.7	2.5 ± 0.6	102 ± 37	53 ± 28[b]	11.2 ± 3.7	31.6 ± 12.1[b]	1802 ± 619	1892 ± 266
PtdIns	6.8 ± 1.8	5.2 ± 1.3[b]	252 ± 110	135 ± 72[b]	1.1 ± 0.3	3.6 ± 0.9[b]	357 ± 72	348 ± 80
PtdSer	1.2 ± 0.4	0.8 ± 0.2[b]	39 ± 16	23 ± 9[b]	2.7 ± 1.2	6.6 ± 2.1[b]	110 ± 21	135 ± 33
ChoGpl	9.3 ± 2.3	7.3 ± 1.1[b]	350 ± 160	186 ± 93[b]	1.4 ± 0.3	4.0 ± 1.4[b]	783 ± 163	901 ± 118
CerPCho	0.8 ± 0.6	0.4 ± 0.2[b]	32 ± 10	11 ± 4[b]	0.9 ± 0.3	3.3 ± 1.6[b]	42 ± 6	38 ± 9

[a] Values represent means ± the standard deviation ($n = 7-9$). Abbreviation: $C_{br,i}$, mass of 20:4n-6 in an individual phospholipid. [b] Statistically significant difference from the value of control mice ($p < 0.05$).

Table 2: Effects of α-Synuclein Ablation on the Unilateral Incorporation Coefficient (k_i*), the Rate of Incorporation into Individual Liver Phospholipid Pools, and Turnover in These Individual Phospholipid Pools[a]

	k_i* ($\times 10^{-5}$ s^{-1})		$J_{FA,i}$ (nmol/h)		$T_{1/2,i}$ (h)		$C_{liv,i}$ (nmol/g wet weight)	
	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$	$Snca^{+/+}$	$Snca^{-/-}$
EtnGpl	42.6 ± 5.8	51.9 ± 14.6	551 ± 207	562 ± 164	1.3 ± 0.5	1.2 ± 0.3	989 ± 148	1045 ± 118
PtdIns	24.2 ± 2.9	23.2 ± 5.4	261 ± 46	233 ± 68	1.7 ± 0.6	1.6 ± 0.5	694 ± 116	627 ± 77
PtdSer	10.0 ± 1.8	9.6 ± 2.9	127 ± 28	107 ± 28	1.1 ± 0.3	1.4 ± 0.5	189 ± 30	180 ± 30
ChoGpl	191.7 ± 15.1	208.3 ± 59.8	2443 ± 817	2271 ± 692	0.6 ± 0.2	0.6 ± 0.2	1935 ± 155	1990 ± 82
CerPCho	4.6 ± 1.0	4.5 ± 1.4	57 ± 18	47 ± 12	1.9 ± 0.5	2.2 ± 0.6	166 ± 14	155 ± 24

[a] Values represent means ± the standard deviation ($n = 7-9$).

FIGURE 3: Uptake of [1-^{14}C]20:4n-6 into brain from *snca$^{-/-}$* and *snca$^{+/+}$* mice expressed as total uptake or uptake into the aqueous and organic brain fractions. Values were normalized to the plasma curve radioactivity and expressed as the unidirectional incorporation coefficient, $k* \times 10^{-5}$ (s^{-1}). Values were corrected for radioactivity associated with the residual blood left in brain and represent means ± the standard deviation ($n = 7-9$). The asterisk indicates a statistically significant difference from *snca$^{+/+}$* mice ($p < 0.05$).

nuclein deficiency decreased the rate of brain 16:0 uptake in vivo (*29*) and reduced the rates of 16:0 and 20:4n-6 uptake in cultured astrocytes (*11*). We assessed the effect of α-synuclein on brain 20:4n-6 uptake in vivo by infusing *Snca$^{+/+}$* and *Snca$^{-/-}$* mice with [1-^{14}C]20:4n-6 (intravenous). There were no differences in input function (integrated plasma radioactivity) for *Snca$^{+/+}$* (1394 ± 445 nCi mL^{-1} min^{-1}) and *Snca$^{-/-}$* (1391 ± 204 nCi mL^{-1} min^{-1}) mice, indicating that there were no overt differences in 20:4n-6 metabolism between groups. In brain extracts, the total and organic (lipid containing) phase incorporation coefficients for *Snca$^{-/-}$* mice were modestly decreased 15 and 12%, respectively, (Figure 3). There was no significant difference in tracer entering the brain aqueous compartment (Figure 3), which represents products of β-oxidation (*46, 67–69*). The lack of a difference in β-oxidation adds additional evidence supporting the idea that the changes observed herein

are the result of altered ER-based Acsl expression or activity, rather than changes in acyl-CoA pools associated with mitochondrial β-oxidation. However, the lack of a large reduction in the rate of brain 20:4n-6 uptake suggests 20:4n-6-CoA formation may account for the reduction observed in 20:4n-6-CoA mass.

Acyl-CoA Synthetase and Hydrolase Expression Is Unaffected by the Lack of α-*Synuclein.* One explanation for the reduction in 20:4n-6-CoA mass would be a reduction in the level of brain acyl-CoA synthetase expression or an increase in the level of brain acyl-CoA hydrolase expression in the *Snca$^{-/-}$* mice. Because *Acsl3, -4,* and *-6* are expressed in brain (*70–75*), we measured the mRNA levels of these three synthetases using Northern blot hybridization and real-time PCR analyses. All three synthetases were equally expressed in *Snca$^{+/+}$* and *Snca$^{-/-}$* mice (Figure 4a). Expression of *Acsl6* was also assessed by real-time PCR relative to a housekeeping mRNA for a housekeeping enzyme, Hprt, and was found to be unchanged in *Snca$^{-/-}$* mice (Figure 4b). We also assessed expression of type II acyl-CoA thioesterase (*Bach*), which is strongly expressed in brain (*76, 77*) and hydrolyzes 20:4n-6-CoA very efficiently (*78*). There were no differences in *Bach* expression (Figure 4a). Although there are other thioesterases (type I), which hydrolyze 20:4n-6-CoA, they do so with much less efficiency, and it seems unlikely that these could account for the observed reduction in brain 20:4n-6-CoA levels. Hence, while acyl-CoA synthetase expression was not altered by α-synuclein deficiency, such measurements do not assess a reduction in enzymatic activity.

The Absence of α-*Synuclein Decreased Brain Microsomal Acyl-CoA Synthetase Activity.* Because α-synuclein deficiency reduced brain 20:4n-6-CoA mass without altering acyl-CoA synthetase and hydrolase expression, we measured acyl-CoA synthetase activities, using 20:4n-6 as a substrate, in whole brain homogenates and in brain microsomal fractions. No differences in acyl-CoA synthetase activity were found in the whole brain homogenate [1.6 ± 0.1 pmol min^{-1} mg^{-1} for *Snca$^{+/+}$* and 1.5 ± 0.1 pmol min^{-1} mg^{-1} for

FIGURE 4: (a) Northern blot analysis of brain acyl-CoA synthetase and acyl-CoA hydrolase mRNA expression in *snca*$^{-/-}$ and *snca*$^{+/+}$ mice. Abbreviations: Acsl, acyl-CoA synthetase mRNA; Bach, acyl-CoA hydrolase mRNA; 36B4, acidic ribosomal phosphoprotein P0 (loading control). (b) Quantitative real-time RT-PCR of Acsl6 mRNA isolated from *snca*$^{-/-}$ and *snca*$^{+/+}$ mice.


FIGURE 5: Acsl activity was measured in brain microsomes as described in Materials and Methods using 20:4n-6 as a substrate. Values represent means ± the standard deviation ($n = 8$). Samples were from individually prepared microsomes isolated from eight *snca*$^{-/-}$ and *snca*$^{+/+}$ mice. The inset is a representative double-reciprocal plot of these data.

Snca$^{-/-}$ ($n = 8$)], consistent with the similar coefficients for incorporation from plasma into the 20:4n-6-CoA pools. These data suggested an alteration in the activity of the endoplasmic reticulum (microsomal) expressed acyl-CoA synthetases which was confirmed using 20:4n-6 as a substrate (Figure 5). Addition of wt mouse α-synuclein to brain microsomes isolated from *snca*$^{-/-}$ mice clearly demonstrates a complete restoration of activity at all but the lowest concentration of 20:4n-6. Indeed, α-synuclein deficiency reduced the V_{max} and K_m for microsomal acyl-CoA synthetase activity, using 20:

Table 3: V_{max} and K_m Values of Acsl Activity with 20:4n-6 as a Substrate Calculated Using Standard Michaelis−Menten Kinetic Analysis^a

	V_{max} (pmol min^{-1} mg^{-1})	K_m (μM)	$V_{max}/K_m \times 10^{-6}$
Snca$^{+/+}$	15.8 ± 1.8	33.7 ± 3.4	0.47 ± 0.05
Snca$^{-/-}$	10.8 ± 0.8^b	28.4 ± 1.5^b	0.38 ± 0.05^b
Snca$^{-/-}$ with wt Snca	17.7 ± 2.1	35.9 ± 4.0	0.49 ± 0.05

^{a} The V_{max}/K_m ratio was also calculated for individual groups. All values represent means ± the standard deviation ($n = 8$). ^{b} Statistically significant difference from those of *Snca*$^{+/+}$ and *Snca*$^{-/-}$ with wt Snca.


FIGURE 6: Western blot analysis confirmed the presence α-synuclein in brain microsomes from *snca*$^{+/+}$ mice used in Figure 5. Microsomes were isolated from mouse brains as described in Materials and Methods. Lanes 1−8 contained 50 μg of total protein from *snca*$^{+/+}$ brain microsomes. The positive control (+) is 0.3 μg of total protein from α-synuclein expressing HEK-293 cells.

4n-6 as a substrate, 32 and 16%, respectively, but these values were completely restored by addition of wt mouse α-synuclein (Table 3). Calculating the ratio of V_{max} to K_m, a situation that may more accurately reflect activity under physiological conditions (*75*), we demonstrate a significant 19% reduction in this ratio in the microsomes from *Snca*$^{-/-}$ mice as compared to control mice. Because ER-localized acyl-CoA synthetase activity is crucial for recycling of 20:4n-6 from phospholipid pools into the 20:4n-6-CoA pool, this reduction in enzymatic activity accounts for the observed increase in the dilution coefficient (λ) (Figure 2b) and the reduction in the rate of 20:4n-6 uptake (Figure 3).

Wt but Not Mutant α-Synuclein Restores Acyl-CoA Synthetase Activity. To further establish a modulatory role for wt α-synuclein on acyl-CoA synthetase activity in the endoplasmic reticulum, we performed an add-back experiment with wt mouse and human α-synuclein and the A30P, E46K, and A53T forms of α-synuclein. Others have shown that α-synuclein is enriched in microsomes (*23*), and total brain protein is comprised of 0.1−1.0% α-synuclein (*79, 80*). We confirmed the presence of α-synuclein in our wt brain microsomes using Western blot analysis (Figure 6). Using a dose−response curve, we established that 0.1−10 wt% mouse and human α-synuclein elicited the same effect on Acsl activity with 20:4n-6 as the substrate (Figure 7a). (Note that this corresponds to a final assay concentration for α-synuclein of 6.3−634 μM.) However, only wt mouse and human α-synuclein increased Acsl activity in *snca*$^{-/-}$ microsomes, while E46K and A53T α-synuclein had no effect on activity (Figure 7b). Surprisingly, A30P α-synuclein depressed enzyme activity. In addition, note that 0.05% α-synuclein had significantly less activity than 0.1% α-synuclein and significantly more activity than 0.01% α-synuclein, indicating that the lower concentration of α-synuclein needed to modulate Acsl activity is quite narrow. Importantly, the mutant forms of α-synuclein did not restore activity, demonstrating an important physiological impact of these mutations on brain 20:4n-6 metabolism. The presence of α-synuclein in microsomes isolated from *Snca*$^{+/+}$ brain

FIGURE 7: (a) Dose−response curve for microsomal Acsl activity in brain microsomes isolated from *snca−/−* mice following incubation for 30 min with 0.01−10% wt (mouse and human), A30P, E46K, and A53T α-synuclein. This corresponds to a final assay concentration of 0.6−634 μM for α-synuclein. Values represent activity in picomoles per minute per milligram of protein ($n = 8$) for each group. The asterisk indicates a statistically significant difference from microsomes deficient in α-synuclein. (b) Restoration of Acsl activity was assessed by measuring Acsl activity in *snca−/−* brain microsomes following the addition of 1.0% wt (mouse and human), A30P, E46K, and A53T α-synuclein. This corresponds to a final assay concentration of 63 μM for the α-synuclein. Microsomes were isolated from eight *snca−/−* mouse brains as described in Materials and Methods. The substrate was 20:4n-6 (190 μM). All experimental groups were assayed in the same experiment. Values represent means ± the standard deviation ($n = 8$). The asterisk indicates a statistically significant difference from *snca+/+* mice ($p < 0.05$), and two asterisks indicate a significant difference from *snca−/−* mice ($p < 0.05$).

and the restoration of acyl-CoA synthetase activity by exogenously supplied α-synuclein demonstrate a clear mechanistic role for α-synuclein in brain 20:4n-6 metabolism. Whether α-synuclein interacts with the enzyme directly or is involved in substrate presentation remains to be determined.

DISCUSSION

There are two major driving forces for cellular fatty acid uptake: binding to proteins (*46, 47, 81−83*) and metabolic utilization, specifically acyl-CoA formation (*84−86*). For instance, expression of Acsl6 in PC-12 cells substantially increases the rate of fatty acid uptake (*84, 86*); on the other

hand, expression of FABP increases the rate of uptake of fatty acid into cells (*81−83*), and the loss of FABP expression reduces the rate of tissue fatty acid uptake in vivo (*46, 47*). We have previously shown in our studies of 16:0 incorporation and turnover in brain phospholipid pools in *Snca−/−* mice that α-synuclein does not bind 16:0, yet *Snca−/−* mice have decreased the rates of 16:0 incorporation and turnover in brain without changing 16:0-CoA mass (*29*), suggesting that altered 16:0 metabolism was the driving force for this reduction in uptake rate. Others have shown that α-synuclein binds oleate (18:1n-9) using a classical Lipidex competition assay (*23*), although we demonstrated no 18: 1n-9 binding using titration microcalorimetry (*29*). Although α-synuclein binds to 20:4n-6, it does so with an affinity considerably lower than that for a classical FABP (*66, 87*), suggesting that the demonstrated effect of α-synuclein on brain fatty acid uptake is more likely linked to acyl-CoA formation rather than fatty acid binding.

The absence of α-synuclein depressed the rate of brain 20:4n-6 uptake and altered fatty acid targeting to the brain organic fraction, although targeting to the aqueous fraction was unaltered (Figure 3). These results are consistent with those observed for uptake of 16:0 into brains lacking α-synuclein (*29*) and with its effect on 20:4n-6 and 16:0 uptake and metabolism in primary astrocytes (*11*). Brain cytosolic, unesterified polyunsaturated fatty acid mass is reduced when α-synuclein is absent (*88*), suggesting a connection between α-synuclein expression and polyunsaturated fatty acids. Reduced coefficients for incorporation of 20:4n-6 into individual brain phospholipids in *Snca−/−* mice account for the observed reduction in the level of targeting to the organic fraction. Thus, there is a modest reduction in the rate of 20:4n-6 uptake in *Snca−/−* mice that is related to the reduced rate of incorporation into brain phospholipid pools.

We also observed a marked reduction in 20:4n-6-CoA mass in *Snca−/−* mice. This reduction was associated with depressed kinetics of incorporation of 20:4n-6 into brain phospholipid pools, as evidenced by the elevation in λ and prolonged half-life for 20:4n-6 in phospholipid pools. The net rate of incorporation of 20:4n-6 from 20:4n-6-CoA into individual phospholipids was decreased 40−65%, and brain individual phospholipid half-lives were increased 2.4−3.7-fold under α-synuclein deficient conditions (Table 1). It is important to note that absolute levels of 20:4n-6 in phospholipid pools were not altered; instead, the kinetics of 20: 4n-6 incorporation and the duration that 20:4n-6 remained on the phospholipid were increased. The dilution coefficient, λ, was increased 3.3-fold in the absence of α-synuclein, indicating that there was significantly less fatty acid recycling from the endogenous pools of 20:4n-6 found in brain phospholipids and more fatty acid entered the 20:4n-6-CoA pool from plasma (Figure 8). These data are consistent with the interpretation that α-synuclein modulates specific brain acyl-CoA synthetases that target fatty acids to phospholipids.

Several mechanisms could lead to decreased 20:4n-6-CoA mass in the absence of α-synuclein. Because α-synuclein overexpression alters expression of acyl-CoA synthetase in *Drosophila* (*35*), we determined if α-synuclein deficiency has an effect on the expression of key enzymes involved in acyl-CoA metabolism (Figure 4a,b). Our data indicate that neither acyl-CoA synthetase expression nor acyl-CoA hy-

FIGURE 8: Model for the role of α-synuclein in brain 20:4n-6 metabolism. Abbreviations: 20:4n-6, arachidonic acid; k^*(20:4-CoA), coefficient for incorporation of 20:4 from plasma into the 20:4-CoA pool; FATP, fatty acid binding protein; [20:4-CoA], mass of 20:4-CoA in tissue; λ, dilution coefficient; incorp. rate 20:4-CoA, net rate of incorporation of 20:4 from 20:4-CoA into individual phospholipids.

drolase expression was altered; hence, this possibility does not account for the reduction in observed 20:4n-6-CoA levels. On the other hand, we demonstrated a 32% reduction in brain microsomal acyl-CoA synthetase activity (V_{max}) in preparations from α-synuclein deficient mouse brains (Figure 5 and Table 3). In addition, the V_{max}/K_m ratio was also significantly depressed in the gene-ablated mice (Table 3), demonstrating that under physiological conditions (75) there would be an effect by α-synuclein on Acsl activity. While we demonstrated the presence of α-synuclen in $Snca^{+/+}$ microsomes (Figure 6), others have also noted that α-synuclein is particularly enriched in microsomal fractions containing primarily ER (23) as well as colocalized with ER in synaptosomal preparations (21, 80, 89), but not found to be associated with synaptic vesicles (80).

More importantly, addition of a physiologically relevant amount of recombinant wt mouse or human α-synuclein completely restored acyl-CoA synthetase activity toward 20:4n-6 (Figure 7a,b). These results indicate that α-synuclein can modulate acyl-CoA synthetase activity, while its mutant (A53T and A30P) forms failed to do so. In fact, A30P significantly reduced acyl-CoA synthetase activity when added to α-synuclein deficient microsomes. Although wt mouse α-synuclein has a natural A53T mutation, it has a number of significant differences in the carboxy tail region as compared to human wt α-synuclein or α-synuclein bearing the A53T mutation. We speculate that these differences may account for the ability of the wt mouse α-synuclein but not the human A53T form of α-synuclein to restore Acsl activity in microsomes isolated from $snca^{-/-}$ mice. These results indicate, for the first time, a significant impact of the mutant forms of α-synuclein on physiological activity, implying a potentially important reduction of brain 20:4n-6 metabolism in subjects expressing these forms.

To address if α-synuclein may be involved in substrate presentation or product removal, we assessed the ability of α-synuclein to bind 20:4n-6 and 20:4n-6-CoA. The lack of 20:4n-6-CoA binding by α-synuclein does not support modulation of acyl-CoA synthetase activity via product removal, while the binding of free 20:4n-6 supports modulation via substrate presentation but does not rule out a direct

protein−protein interaction. These results clearly indicate that α-synuclein interacts with the enzyme in a manner that modulates activity, either by a direct protein−protein interaction or through substrate presentation.

Although microsomal Acsl activity was significantly reduced in $Snca^{-/-}$ brains, total brain acyl-CoA synthetase activity toward 20:4n-6 was not altered. This lack of altered activity for total brain acyl-CoA formation is consistent with the similar coefficients (k^*) of incorporation from plasma into the 20:4n-6-CoA pools. Taken together, these data indicate that α-synuclein modulates specific acyl-CoA synthetase pools. Acyl-CoA pools are spatially arranged in organelles, with pools ranging from the mitochondrial pool to those in the endoplasmic reticulum (29). The lack of differences in the amount of tracer entering brain aqueous fraction, which represents products of β-oxidation (46, 67−69) (Figure 3), indicates that α-synuclein does not impact the mitochondrial pool relative to the endoplasmic reticulum pool, similar to the effect observed using 16:0 (29). Moreover, fatty acid transport protein (FATP) is associated with plasma membrane and exhibits both fatty acid transport and acyl-CoA synthetase activities (90−92), and FATP-4 is expressed in the brain (93). The potential involvement of this enzyme in acyl-CoA formation may account for the lack of differences between the groups in whole brain homogenate acyl-CoA activity and the similar coefficients for incorporation of 20:4n-6 from the plasma into the total brain acyl-CoA pool. This suggests that α-synuclein modulates specific acyl-CoA synthetases localized in the ER, consistent with our data presented above. Taking into account the fact that brain Acsl6 targets fatty acids to phospholipids and neutral lipids (84) but that Ascl1 targets fatty acids only to triglycerides (75), we speculate that α-synuclein selectively affects one or more specific acyl-CoA synthetases (Acsl3, -4, or -6) associated with phospholipid synthesis. It is important to note that in α-synuclein deficient astrocytes, there is significantly more fatty acid targeted for incorporation into neutral lipids, e.g., triacylglycerols and cholesteryl esters as well as a substantial increase in neutral lipid mass (11). In addition, brain neutral lipid mass was also increased in the $Snca^{-/-}$ brains (unpublished data), suggesting a similar situation occurs in vivo.

Collectively, our results demonstrate that α-synuclein is critical for maintenance of brain 20:4n-6-CoA levels that are absolutely essential for incorporation of 20:4n-6 into brain phospholipid pools (Figure 6). This effect on metabolism accounts for the small but significant reduction in the rate of 20:4n-6 uptake. There was a large reduction in 20:4n-6-CoA mass in $Snca^{-/-}$ brains, resulting from a reduction in endoplasmic reticulum (microsomal) acyl-CoA synthetase activity. This reduction in activity decreased the net 20:4n-6-CoA pool size, which caused a substrate limiting reduction in 20:4n-6-CoA resulting in the decreased level of incorporation into individual phospholipids. As a result, the half-life of individual phospholipids was increased, indicating less recycling of 20:4n-6 from endogenous phospholipid stores. These results are important because they are the first demonstration that α-synuclein impacts brain 20:4n-6 metabolism through modulation of an ER-based acyl-CoA synthetase rather than through the influence on fatty acid uptake via the direct binding of 20:4n-6 by α-synuclein. Because of the fundamental importance of 20:4n-6 metabo-

lism in brain function, we demonstrate herein a key means of regulating 20:4n-6 metabolism through modulation of brain 20:4n-6-CoA pools, thereby providing a means of channeling 20:4n-6 to phospholipids. This newly described physiological function for α-synuclein provides a broader view of how it regulates brain lipid metabolism and how changes in this protein may impact brain function, contributing to the pathophysiology associated with neurodegenerative disease. In addition, we demonstrate the inability of the mutant forms of α-synuclein to restore brain microsomal 20:4n-6-CoA production via microsomal Acsl, suggesting a potentially critical reduction in the rate of 20:4n-6 metabolism in subjects expressing these mutant forms of α-synuclein.

ACKNOWLEDGMENT

REFERENCES

1. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain, *FEBS Lett. 345*, 27–32.
2. Lavedan, C. (1998) The synuclein family, *Genome Res. 8*, 871–880.
3. Maroteaux, L., Campanelli, J. T., and Scheller, R. H. (1988) Synuclein: A neuron-specific protein localized in the nucleus and presynaptic nerve terminal, *J. Neurosci. 8*, 2804–2815.
4. Jo, E., McLaurin, J., Yip, C. M., St. George-Hyslop, P., and Fraser, P. E. (2000) α-Synuclein membrane interactions and lipid specificity, *J. Biol. Chem. 275*, 34328–34334.
5. McLean, P. J., Ribich, S., and Hyman, B. T. (2000) Subcellular localization of α-synuclein in primary neuronal cultures: Effect of missense mutations, *J. Neural Transm., Suppl. 58*, 53–63.
6. Richter-Landsberg, C., Gorath, M., Trojanowski, J. Q., and Lee, V. M. (2000) α-Synuclein is developmentally expressed in cultured rat brain oligodendrocytes, *J. Neurosci. Res. 62*, 9–14.
7. Mori, F., Tanji, K., Yoshimoto, M., Takahashi, H., and Wakabayashi, K. (2002) Demonstration of α-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinkinase K and formic acid pretreatment, *Exp. Neurol. 176*, 98–104.
8. Cheng, S. Y., and Trombetta, L. D. (2004) The induction of amyloid precursor protein and α-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione, *Toxicol. Lett. 146*, 139–149.
9. Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S. T., Paik, S. R., and Chung, K. C. (2005) Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases, *J. Biol. Chem. 280*, 25216–25224.
10. Ziolkowska, B., Gieryk, A., Bilecki, W., Wawrzczak-Bargiela, A., Wedzony, K., Chocyk, A., Danielson, P. E., Thomas, E. A., Hilbush, B. S., Sutcliff, J. G., and Przewlocki, R. (2005) Regulation of α-synuclein expression in limbic and motor brain regions of morphine-treated mice, *J. Neurosci. 25*, 4996–5003.
11. Castagnet, P. I., Golovko, M. Y., Barceló-Coblijn, G. C., Nussbaum, R. L., and Murphy, E. J. (2005) Fatty acid incorporation is decreased in astrocytes cultured from α-synuclein gene-ablated mice, *J. Neurochem. 94*, 839–849.
12. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., DiIorio, G., Golbe, L. I., and Nussbaum, R. L. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease, *Science 276*, 2045–2047.
13. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, S., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Reiss, O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease, *Nat. Genet. 18*, 106–108.
14. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) α-Synuclein locus triplication causes Parkinson's disease, *Science 302*, 841.
15. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, D. G., and de Yebenes, J. G. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy Body dementia, *Ann. Neurol. 55*, 164–173.
16. Trojanowski, J. Q., Goedert, M., Iwatsubo, T., and Lee, V. M. (1998) Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia, *Cell Death Differ. 5*, 832–837.
17. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., and Goedert, M. (1998) Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, *Neurosci. Lett. 251*, 205–208.
18. Takeda, A., Hashimoto, M., Mallory, M., Sundsumo, M., Hansen, L., Sisk, A., and Masliah, E. (1998) Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment, *Lab. Invest. 78*, 1169–1177.
19. Lippa, C. F., Schmidt, M. L., Lee, V. M., and Trojanowski, J. Q. (1999) Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease, *Ann. Neurol. 45*, 353–357.
20. Iseki, E., Marui, W., Kosaka, K., Akiyama, H., Ueda, K., and Iwatsubo, T. (1998) Degenerative terminals of the perforant pathway are human α-synuclein-immunoreactive in the hippocampus of patients with diffuse Lewy body disease, *Neurosci. Lett. 258*, 81–84.
21. George, J. M., Jin, H., Woods, W. S., and Clayton, D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch, *Neuron 15*, 361–372.
22. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes, *J. Biol. Chem. 273*, 9443–9449.
23. Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., and Selkoe, D. J. (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins, *Proc. Natl. Acad. Sci. U.S.A. 98*, 9110–9115.
24. Narayanan, V., and Scarlata, S. (2001) Membrane binding and self-association of α-synucleins, *Biochemistry 40*, 9927–9934.
25. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2001) Exposure to long-chain polyunsaturated fatty acids triggers rapid multimerization of synucleins, *J. Biol. Chem. 276*, 41958–41962.
26. Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., and Goedert, M. (1998) Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation, *J. Biol. Chem. 273*, 26292–26294.
27. Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., and Lee, V. M. (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons, *J. Neurosci. 20*, 3214–3220.
28. Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. C., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., Lu, B., and Nussbaum, R. L. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein, *J. Neurosci. 22*, 8797–8807.
29. Golovko, M. Y., Faergeman, N. J., Cole, N. B., Castagnet, P. I., Nussbaum, R. L., and Murphy, E. J. (2005) α-Synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of α-synuclein palmitate binding, *Biochemistry 44*, 8251–8259.
30. Ellis, C. E., Murphy, E. J., Mitchell, D. C., Golovko, M. Y., Scaglia, F., Barcelo-Coblijn, G., and Nussbaum, R. L. (2005) Mitochondrial lipids abnormality and electron transport chain impairment in mice lacking α-synuclein, *Mol. Cell. Biol. 25*, 10190–10201.
31. Jenco, J. M., Rawlingson, A., Daniels, B., and Morris, A. J. (1998) Regulation of phospholipase D2: Selective inhibition of mam-

malian phospholipase D isoenzymes by α- and β-synucleins, *Biochemistry 37*, 4901−4909.

32. Payton, J. E., Perrin, R. J., Woods, W. S., and George, J. M. (2004) Structural determinants of PLD2 inhibition by α-synuclein, *J. Mol. Biol. 337*, 1001−1009.

33. Narayanan, V., Guo, Y., and Scarlata, S. (2005) Fluorescence studies suggest a role for α-synuclein in the phosphatidylinositol lipid signaling pathway, *Biochemistry 44*, 462−470.

34. Outeiro, T. F., and Lindquist, S. (2003) Yeast cells provide insight into α-synuclein biology and pathobiology, *Science 302*, 1772−1775.

35. Scherzer, C. R., Jensen, R. V., Gullans, S. R., and Feany, M. B. (2003) Gene expression changes presage neurodegeneration in a *Drosophila* model of Parkinson's disease, *Hum. Mol. Genet. 12*, 2457−2466.

36. Rosenberger, T. A., Villacreses, N. E., Contreras, M. A., Bonventre, J. V., and Rapoport, S. I. (2003) Brain lipid metabolism in the cPLA$_2$ knockout mouse, *J. Lipid Res. 44*, 109−117.

37. Lesa, G. M., Palfreyman, M., Hall, D. H., Clandinin, M. T., Rudolph, C., Jorgensen, E. M., and Schiavo, G. (2003) Long chain polyunsaturated fatty acids are required for efficient neurotransmission in *C. elegans*, *J. Cell Sci. 116*, 4965−4975.

38. Bazan, N. G. (2003) Synaptic lipid signaling: Significance of polyunsaturated fatty acis and platelet-activating factor, *J. Lipid Res. 44*, 2221−2233.

39. Williams, J. H., Errington, M. L., Lynch, M. A., and Bliss, T. V. P. (1989) Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus, *Nature 341*, 739−742.

40. Wolf, M. J., Izumi, Y., Zorumski, C. F., and Gross, R. W. (1995) Long-term potentiation requires activation of calcium-independent phospholipase A$_2$, *FEBS Lett. 377*, 358−362.

41. Massicotte, G., Vanderklish, P., Lynch, G., and Baudry, M. (1991) Modulation of a DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/quisqualate receptors by phospholipase A$_2$: A necessary step in long-term potentiation, *Proc. Natl. Acad. Sci. U.S.A. 88*, 1893−1897.

42. Lee, H., Villacreses, N. E., Rapoport, S. I., and Rosenberger, T. A. (2004) *In vivo* imaging detects a transient increase in brain arachidonic acid metabolism: A potential marker of neuroinflammation, *J. Neurochem. 91*, 936−945.

43. Bazan, N. G. (1971) Changes in free fatty acids of brain by drug-induced convulsions, electroshock and anesthesia, *J. Neurochem. 18*, 1379−1385.

44. Rosenberger, T. A., Villacreses, N. E., Hovda, J. T., Boestti, F., Weerasinghe, G., Wine, R. N., Harry, G. J., and Rapoport, S. I. (2004) Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide, *J. Neurochem. 88*, 1168−1178.

45. Arai, K., Ikegaya, Y., Nakatani, Y., Kudo, I., Nishiyama, N., and Matsuki, N. (2001) Phospholipase A$_2$ mediates ischemic injury in the hippocampus: A regional difference of neuronal vulnerability, *Eur. J. Neurosci. 13*, 2319−2323.

46. Murphy, E. J., Barcelo-Coblijn, G., Binas, B., and Glatz, J. F. (2004) Heart fatty acid uptake is decreased in heart-fatty acid binding protein gene-ablated mice, *J. Biol. Chem. 279*, 34481−34488.

47. Murphy, E. J., Owada, Y., Kitanaka, N., Konda, H., and Glatz, J. F. C. (2005) Brain arachidonic acid incorporation is decreased in heart-fatty acid binding protein gene-ablated mice, *Biochemistry 44*, 6350−6360.

48. Folch, J., Lees, M., and Sloan Stanley, G. H. (1957) A simple method for the isolation and purification of total lipides from animal tissues, *J. Biol. Chem. 226*, 497−509.

49. Jolly, C. A., Hubbell, T., Behnke, W. D., and Schroeder, F. (1997) Fatty acid binding protein: Stimulation of microsomal phosphatidic acid formation, *Arch. Biochem. Biophys. 341*, 112−121.

50. Marcheselli, V. L., Scott, B. L., Reddy, T. S., and Bazan, N. G. (1988) Quantitative analysis of acyl group composition of brain phospholipids, neutral lipids, and free fatty acids, in *Neuromethods 7: Lipids and Related Compounds* (Boulton, A. A., Baker, G. B., and Horrocks, L. A., Eds.) pp 83−110, Humana Press, Clifton, NJ.

51. Brockerhoff, H. (1975) Determination of the positional distribution of fatty acids in glycerolipids, *Methods Enzymol. 35*, 315−325.

52. Akesson, B., Elovsson, J., and Arvidsson, G. (1970) Initial incorporation into rat liver glycerolipids of intraportally injected [^{3}H]glycerol, *Biochim. Biophys. Acta 210*, 15−27.

53. Golovko, M. Y., and Murphy, E. J. (2004) An improved method for tissue long chain acyl-CoA extraction and analysis, *J. Lipid Res. 45*, 1777−1782.

54. Robinson, P. J., Noronha, J., DeGeorge, J. J., Freed, L. M., Nariai, T., and Rapoport, S. I. (1992) A quantitative method for measuring regional in vivo fatty acid incorporation into and turnover within brain phospholipids: Review and critical analysis, *Brain Res. Rev. 17*, 187−214.

55. Rapoport, S. I., Chang, M. C. J., and Spector, A. A. (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain, *J. Lipid Res. 42*, 678−685.

56. Rosenberger, T. A., Oki, J., Purdon, A. D., Rapoport, S. I., and Murphy, E. J. (2002) Rapid synthesis and turnover of brain microsomal ether phospholipids in the adult rat, *J. Lipid Res. 43*, 59−68.

57. Rolf, B., Oudenampsen-Krüger, E., Börchers, T., Færgeman, N. J., Knudsen, J., Lezius, A., and Spener, F. (1995) Analysis of the ligand binding properties of recombinant bovine liver-type fatty acid binding protein, *Biochim. Biophys. Acta 1259*, 245−253.

58. Sigurskjold, B. W., Altman, E., and Bundle, D. R. (1991) Sensitive titration microcalorimetric study of the binding of *Salmonella* O-antigenic oligosaccharides by a monoclonal antibody, *Eur. J. Biochem. 197*, 239−246.

59. Faergeman, N. J., Sigurskjold, B. W., Kragelund, B. B., Andersen, K. V., and Knudsen, J. (1996) Thermodynamics of ligand binding to acyl-coenzyme A binding protein studied by titration calorimetry, *Biochemistry 35*, 14118−14126.

60. Fraisl, P., Forss-Petter, S., Zigman, M., and Berger, J. (2004) Murine bubblegum orthologue is a microsomal very-long-chain acyl-CoA synthetase, *Biochem. J. 377*, 85−93.

61. Wilson, D. B., Prescott, S. M., and Majerus, P. W. (1982) Discovery of an arachidonoyl coenzyme A synthetase in human platelets, *J. Biol. Chem. 257*, 3510−3515.

62. Saunders, C., Voigt, J. M., and Weis, M. T. (1996) Evidence for a single non-arachidonic acid-specific fatty acyl-CoA synthetase in heart which is regulated by Mg^{2+}, *Biochem. J. 313*, 849−853.

63. Bradford, M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, *Anal. Biochem. 72*, 248−254.

64. Cole, N. B., Murphy, D. D., Lebowitz, J., DiNoto, L., Levine, R. L., and Nussbaum, R. L. (2005) Metal-catalyzed oxidation of α-synuclein: Helping to define the relationship between oligomers, protofilaments and filaments, *J. Biol. Chem. 280*, 9678−9690.

65. Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., and Nussbaum, R. L. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein, *J. Biol. Chem. 277*, 6344−6352.

66. Richieri, G. V., Ogata, R. T., and Kleinfeld, A. M. (1994) Equilibrium constants for the binding of fatty acids with fatty acid-binding proteins from adipocyte, intestine, heart, and liver measured with the fluorescent probe ADIFAB, *J. Biol. Chem. 269*, 23918−23930.

67. Miller, J. C., Gnaedinger, J. M., and Rapoport, S. I. (1987) Utilization of plasma fatty acid in rat brain: Distribution of [^{14}C]-palmitate between oxidative and synthetic pathways, *J. Neurochem. 49*, 1507−1514.

68. Gnaedinger, J. M., Miller, J. C., Latker, C. H., and Rapoport, S. I. (1988) Cerebral metabolism of plasma [^{14}C]palmitate in awake adult rat: Subcellular localization, *Neurochem. Res. 13*, 21−29.

69. Murphy, E. J., Rosenberger, T. A., Patrick, C. B., and Rapoport, S. I. (2000) Intravenously injected [1-^{14}C]arachidonic acid targets phospholipids, and [1-^{14}C]palmitic acid targets neutral lipids in hearts of awake rats, *Lipids 35*, 891−898.

70. Iijima, H., Fujino, T., Minekura, H., Suzuki, H., Kang, M. J., and Yamamoto, T. (1996) Biochemical studies of two rat acyl-CoA synthetases, ACS-1 and ACS-2, *Eur. J. Biochem. 242*, 196−190.

71. Oikawa, E., Iijima, H., Suzuki, T., Sasano, H., Sato, H., Kamataki, A., Nagura, H., Kang, M. J., Fujino, T., Suzuki, H., and Yamamoto, T. T. (1998) A novel acyl-CoA synthetase, ACS5, expressed in intestinal epithelial cells and proliferating preadipocytes, *J. Biochem. 124*, 679−685.

72. Kang, M.-J., Fujino, T., Sasano, H., Minekura, H., Yabuki, N., Nagura, H., Iijima, H., and Yamamoto, T. T. (1997) A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis, *Proc. Natl. Acad. Sci. U.S.A. 94*, 2880−2884.

73. Fugino, T., Kang, M.-J., Suzuki, H., Iijima, H., and Yamamoto, T. (1996) Molecular characterization and expression of rat acyl-CoA synthetase 3, *J. Biol. Chem. 271*, 16748−16752.

74. Lee, E. J., Kim, H. C., Cho, Y. Y., Byun, S. J., Lim, J. M., and Ryoo, Z. Y. (2005) Alternative promotion of the mouse acyl-CoA synthetase 6 (mAcsl6) gene mediates the expression of multiple transcripts with 5′-end heterogeneity: Genetic organization of mAcsl6 variants, *Biochem. Biophys. Res. Commun. 327*, 84−93.

75. Van Horn, C. G., Caviglia, J. M., Lei, O. L., Wang, S., Granger, D. A., and Coleman, R. A. (2005) Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: Identification of a novel variant of isoform 6, *Biochemistry 44*, 1635−1642.

76. Kuramochi, Y., Takagi-Sakuma, M., Kitahara, M., Emori, R., Asaba, Y., Sakaguchi, R., Watanabe, T., Kuroda, J., Hiratsuka, K., Nagae, Y., Suga, T., and Yamada, J. (2002) Characterization of mouse homolog of brain acyl-CoA hydrolase: Molecular cloning and neuronal localization, *Brain Res. Mol. Brain Res. 98*, 81−92.

77. Yamada, J., Kuramochi, Y., Takagi, M., Watanabe, T., and Suga, T. (2002) Human brain acyl-CoA hydrolase isoforms encoded by a single gene, *Biochem. Biophys. Res. Commun. 299*, 49−56.

78. Broustas, C. G., and Hajra, A. K. (1995) Purification, properties, and specificity of rat brain cytosolic fatty acyl coenzyme A hydrolase, *J. Neurochem. 64*, 2345−2353.

79. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., Kittel, A., and Saitoh, T. (1995) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, *Neuron 14*, 467−475.

80. Shibayama-Imazu, T., Okahashi, I., Omata, K., Nakajo, S., Ochiai, H., Nakai, Y., Hama, T., Nakamura, Y., and Nakaya, K. (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phoshoneuroprotein 14), *Brain Res. 622*, 17−25.

81. Murphy, E. J., Prows, D. R., Jefferson, J. R., and Schroeder, F. (1996) Liver fatty acid binding protein expression in transfected fibroblasts stimulates fatty acid uptake and metabolism, *Biochim. Biophys. Acta 1301*, 191−196.

82. Prows, D. R., Murphy, E. J., and Schroeder, F. (1995) Intestinal and liver fatty acid binding proteins differentially affect fatty acid uptake and esterification in L-cells, *Lipids 30*, 907−910.

83. Murphy, E. J. (1998) L-FABP and L-FABP expression increases NBD-stearate uptake and cytoplasmic diffusion in L cells, *Am. J. Physiol. 275*, G244−G249.

84. Marszalek, J. R., Kitidis, C., DiRusso, C. C., and Lodish, H. F. (2005) Long-chain acyl-CoA synthetase 6 preferentially promotes DHA metabolism, *J. Biol. Chem. 280*, 10817−10826.

85. Muoio, D. M., Lewin, T. M., Wiedmer, P., and Coleman, R. A. (2000) Acyl-CoAs are functionally channeled in liver: Potential role of acyl-CoA synthetase, *Am. J. Physiol. 279*, E1366−E1373.

86. Marszalek, J. R., Kitidis, C., Dararutana, A., and Lodish, H. F. (2004) Acyl-CoA synthetase 2 overexpression enhances fatty acid internalization and neurite outgrowth, *J. Biol. Chem. 279*, 23882−23891.

87. Richieri, G. V., Ogata, R. T., Zimmerman, A. W., Veerkamp, J. H., and Kleinfeld, A. M. (2000) Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions, *Biochemistry 39*, 7197−7204.

88. Sharon, R., Bar-Joseph, I., Mirick, G. E., Serhan, C. N., and Selkoe, D. J. (2003) Altered fatty acid composition of dopaminergic neurons expressing α-synuclein and human brains with α-synucleinopathies, *J. Biol. Chem. 278*, 49874−49881.

89. Kahle, P. J., Neumann, M., Ozman, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H. A., and Haass, C. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain, *J. Neurosci. 20*, 6365−6373.

90. Hall, A. M., Smith, A. J., and Bernlohr, D. A. (2003) Characterization of the Acyl-CoA synthetase activity of purified murine fatty acid transport protein 1, *J. Biol. Chem. 278*, 43008−43013.

91. Hall, A. M., Wiczer, B. M., Herrmann, T., Stremmel, W., and Bernlohr, D. A. (2005) Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice, *J. Biol. Chem. 280*, 11948−11954.

92. DiRusso, C. C., Li, H., Darwis, D., Watkins, P. A., Berger, J., and Black, P. N. (2005) Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast, *J. Biol. Chem. 280*, 16829−16837.

93. Herrmann, T., Buchkremer, F., Gosch, I., Hall, A. M., Bernlohr, D. A., and Stremmel, W. (2001) Mouse fatty acid transport protein 4 (FATP4): Characterization of the gene and functional assessment as a very long chain acyl-CoA synthetase, *Gene 270*, 31−40.